Expression and clinical significance of Apollon in esophageal squamous cell carcinoma. 2016

Rong Li, and Bo-Lin Chen, and Yan-Wu Zhou, and Ren-Wei Guo, and Meng-Ting Shuai, and Jun-Xian Zeng, and Ai-Min Leng
Department of Gastroenterology, Xiangya Hospital, Changsha, Hunan 410008, P.R. China.

Apollon, an unusually large member of the inhibitors of apoptosis protein family, may be important for oncogenesis development. The aim of the present study was to assess the association between esophageal squamous cell carcinoma (ESCC) and Apollon expression levels, and to highlight the association between Apollon and the occurrence, development and prognosis of ESCC. Apollon expression was detected by immunohistochemical staining and reverse transcription-quantitative polymerase chain reaction in ESCC tissues, adjacent non‑cancerous tissues and paired normal tissues respectively, in order to analyze the association between Apollon expression and the clinicopathological features of ESCC. Survival analysis was used to assess the prognostic significance of Apollon expression. It was determined that the mRNA and protein expression levels of Apollon were significantly higher in the carcinoma tissues compared with the adjacent non‑cancerous tissues and normal control tissues (P<0.001). There was a significant difference in lymph node involvement and the tumor, nodes, and metastases stage in patients categorized according to different Apollon expression levels. The prognostic significance of Apollon was also determined using the log‑rank method. The overexpression of Apollon was associated with shorter overall survival and disease-free survival rates. The present study indicates that Apollon expression is associated with the biological characteristics of ESCC, and may be a valuable prognostic factor and a novel chemotherapeutic target for ESCC treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077277 Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer. Oesophageal Squamous Cell Carcinoma
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Rong Li, and Bo-Lin Chen, and Yan-Wu Zhou, and Ren-Wei Guo, and Meng-Ting Shuai, and Jun-Xian Zeng, and Ai-Min Leng
August 2014, Oncotarget,
Rong Li, and Bo-Lin Chen, and Yan-Wu Zhou, and Ren-Wei Guo, and Meng-Ting Shuai, and Jun-Xian Zeng, and Ai-Min Leng
December 2016, Oncology letters,
Rong Li, and Bo-Lin Chen, and Yan-Wu Zhou, and Ren-Wei Guo, and Meng-Ting Shuai, and Jun-Xian Zeng, and Ai-Min Leng
November 2011, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Rong Li, and Bo-Lin Chen, and Yan-Wu Zhou, and Ren-Wei Guo, and Meng-Ting Shuai, and Jun-Xian Zeng, and Ai-Min Leng
September 2019, Mathematical biosciences and engineering : MBE,
Rong Li, and Bo-Lin Chen, and Yan-Wu Zhou, and Ren-Wei Guo, and Meng-Ting Shuai, and Jun-Xian Zeng, and Ai-Min Leng
August 2011, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Rong Li, and Bo-Lin Chen, and Yan-Wu Zhou, and Ren-Wei Guo, and Meng-Ting Shuai, and Jun-Xian Zeng, and Ai-Min Leng
February 2017, Molecular medicine reports,
Rong Li, and Bo-Lin Chen, and Yan-Wu Zhou, and Ren-Wei Guo, and Meng-Ting Shuai, and Jun-Xian Zeng, and Ai-Min Leng
March 2017, Medical oncology (Northwood, London, England),
Rong Li, and Bo-Lin Chen, and Yan-Wu Zhou, and Ren-Wei Guo, and Meng-Ting Shuai, and Jun-Xian Zeng, and Ai-Min Leng
April 2015, Genetic testing and molecular biomarkers,
Rong Li, and Bo-Lin Chen, and Yan-Wu Zhou, and Ren-Wei Guo, and Meng-Ting Shuai, and Jun-Xian Zeng, and Ai-Min Leng
January 2018, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Rong Li, and Bo-Lin Chen, and Yan-Wu Zhou, and Ren-Wei Guo, and Meng-Ting Shuai, and Jun-Xian Zeng, and Ai-Min Leng
January 2015, Neoplasma,
Copied contents to your clipboard!